JAGX Jaguar Health, Inc.Stock Price & Overview
$0.26
Charts
Quant Ranking
JAGX Analysis
JAGX News
Latest Headlines
Ratings Summary
People Also Follow
Similar to JAGX
ETFs Holding JAGX
JAGX Company Profile
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company’s products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
JAGX Revenue
JAGX Earnings Per Share
Earnings Estimates
Earnings Revisions
Valuation
Growth
Profitability
Momentum
Capital Structure
Dividends
JAGX Ownership
JAGX Peers
Risk
Technicals
JAGX Transcripts
Investor Presentations
JAGX SEC Filings
Press Releases
JAGX Income Statement
JAGX Balance Sheet
JAGX Cash Flow Statement
JAGX Long Term Solvency
Discover More
You may be interested in: